Covington & Burling advised Insmed Incorporated on the transaction. Insmed Incorporated (Nasdaq: INSM) (“Insmed”) announced its entrance into an agreement to amend its $350 million term...
You must be a Standard 1 Year member to access this content.
Covington & Burling advised Selecta Biosciences, Inc. on the transaction, and Foley Hoag advised Cartesian Therapeutics. Selecta Biosciences (Nasdaq:SELB) (“Selecta”) announced its merger with Cartesian Therapeutics and concurrent...
You must be a Standard 1 Year member to access this content.
Covington advised Humacyte on the deal. Humacyte, Inc. announced its $150 million revenue-based funding arrangement, as well as a $10 million equity investment option, with Oberland...
You must be a Standard 1 Year member to access this content.
Covington advised Insmed Incorporated on the deal while Fenwick represented Pharmakon. Walder Wyss advised the funds managed by Pharmakon Advisors, LP, BioPharma Credit and OrbiMed. Akin...
You must be a Standard 1 Year member to access this content.
